Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
Orchard Therapeutics plc (ORTX) CEO Bobby Gaspar on Q2 2020 Results - Earnings Call Transcript
07:32pm, Saturday, 08'th Aug 2020
Orchard Therapeutics plc (NASDAQ:ORTX) Q2 2020 Results Conference Call August 06, 2020 08:00 AM ET Company Participants Renee Leck - Investor Relations Bobby Gaspar - Chief Executive Officer Frank Tho
Passage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020
08:01pm, Friday, 07'th Aug 2020
PHILADELPHIA, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system
Passage Bio Added to Russell 2000 Index
12:00pm, Friday, 26'th Jun 2020
PHILADELPHIA, June 26, 2020 -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous.
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
03:17pm, Thursday, 04'th Jun 2020
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
Passage Bio to Present at Goldman Sachs 41st Annual Global Healthcare Conference
12:00pm, Thursday, 04'th Jun 2020
PHILADELPHIA, June 04, 2020 -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous.
Companies Like Passage Bio (NASDAQ:PASG) Are In A Position To Invest In Growth
12:35pm, Thursday, 28'th May 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis
12:00pm, Thursday, 21'st May 2020
Passage Bio, Inc. (PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced the U.S. Food and Drug Admini
– Preclinical data from University of Pennsylvania’s Gene Therapy Program demonstrate single injection of AAVhu68 carrying a functional GALC gene resulted in normalization of.
Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights
11:00am, Monday, 11'th May 2020
– Expansion of gene therapy collaboration with University of Pennsylvania’s Gene Therapy Program extends collaboration by three additional years and adds five new programs –.
Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania
11:30am, Thursday, 07'th May 2020
Passage Bio, Inc. (PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders and the Gene Therapy Program (GTP) at th
Passage Bio to Report First Quarter 2020 Financial Results on May 11, 2020
12:00pm, Monday, 04'th May 2020
PHILADELPHIA, May 04, 2020 -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous.
Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders
12:00pm, Wednesday, 29'th Apr 2020
Some former executives and investors behind the second gene therapy to win FDA approval are teaming up again. Their new company, Taysha Gene Therapies, is
FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis
12:00pm, Tuesday, 21'st Apr 2020
Passage Bio, Inc. (PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the U.S. Food and Drug A
Passage Bio (NASDAQ:PASG) Rating Increased to Buy at Zacks Investment Research
09:50am, Friday, 10'th Apr 2020
Passage Bio (NASDAQ:PASG) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday, Zacks.com reports. The brokerage cu
Passage Bio to Present at 19th Annual Needham Healthcare Conference
12:00pm, Wednesday, 08'th Apr 2020
PHILADELPHIA, April 08, 2020 -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous.
